16.87
-0.035(-0.21%)
Currency In USD
| Previous Close | 16.91 |
| Open | 17 |
| Day High | 17.17 |
| Day Low | 16.77 |
| 52-Week High | 25.67 |
| 52-Week Low | 13.5 |
| Volume | 2.79M |
| Average Volume | 3.23M |
| Market Cap | 4.03B |
| PE | 19.85 |
| EPS | 0.85 |
| Moving Average 50 Days | 17.69 |
| Moving Average 200 Days | 18.65 |
| Change | -0.04 |
If you invested $1000 in ADMA Biologics, Inc. (ADMA) 10 years ago, it would be worth $1,895.51 as of September 08, 2025 at a share price of $16.87. Whereas If you bought $1000 worth of ADMA Biologics, Inc. (ADMA) shares 5 years ago, it would be worth $7,366.81 as of September 08, 2025 at a share price of $16.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 11:00 AM GMT
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical c
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire Inc.
Apr 30, 2025 11:00 AM GMT
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical com
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R&D